Pfizer partners with molecular glue startup Triana Biomedicines in $49M...
Pfizer is deepening its investment in protein degraders through a new partnership with Triana Biomedicines, a startup working in the trendy field of molecular glues. The companies will work on multiple...
View ArticleClik here to view.
Walgreens plans to close 1,200 pharmacies
Walgreens is closing 1,200 stores, or 14% of its locations, as it fights to turn around its business. The retail pharmacy chain will be closing the stores over the next three years, the company said in...
View ArticleMeiraGTx's stock rises on small Parkinson's gene therapy dataset
MeiraGTx unveiled results from a small dataset for its Parkinson’s disease gene therapy on Tuesday morning, causing its shares $MGTX to jump by as much as 24%. In what the company called a “bridging...
View ArticleCycle makes another offer for Vanda; Ocean Biomedical, Molecure ink new deal
Plus, news about Gilead Sciences and Yuhan: Vanda gets second unsolicited offer: Cycle Group Holdings again submitted a proposal to buy Vanda for $8 per share in cash. Vanda, which is currently trading...
View ArticleJ&J trims pipeline, including two mid-stage neuroscience studies
Johnson & Johnson cut a handful of trials across its portfolio in the third quarter, including a Phase 2 study of a touted neuroscience treatment. Missing in the company’s updated pipeline list is...
View ArticleClik here to view.
First patient who received engineered B cell therapy sees early promise for...
Immusoft gave a glimpse on Monday at how the first patient to ever receive an engineered B cell therapy is doing nine months after being dosed, suggesting that the treatment has been safe so far and is...
View ArticleClik here to view.
J&J’s medtech slump continues, improvements not expected until 2025
Johnson & Johnson beat investors’ expectations despite its medtech unit underperforming, with execs pointing to the Asia-Pacific region as a continued source of struggle. Executives said on the...
View ArticleClik here to view.
Jazz reports Phase 3 success for Zepzelca in first-line maintenance for small...
Jazz Pharmaceuticals announced Tuesday that adding its small cell lung cancer drug Zepzelca to a maintenance treatment regimen for extensive-stage small cell lung cancer cut the risk of death in a...
View ArticleGSK sues Moderna over mRNA vaccine patents, seeks 'reasonable royalty'
GSK on Tuesday unveiled a lawsuit filed against Moderna in Delaware federal court, alleging that its patented inventions provide the “foundation” for Moderna’s mRNA vaccine portfolio. GSK said it’s...
View ArticleSacklers call opioid-related fraud claims 'utterly meritless'
Months after Purdue Pharma’s bankruptcy plan was foiled by the Supreme Court, its previous owners are bracing for a legal battle with creditors. The Sacklers responded on Monday to claims they...
View ArticleGLP-1 side effect treatment data released by Neurogastrx
Neurogastrx believes its drug could treat one of the most troublesome side effects of one of the industry’s biggest blockbusters. On Wednesday, the Boston-area biotech said that its experimental drug,...
View ArticleTakeda parts ways with Wave Life Sciences even with Huntington’s trial win
Takeda will not move forward with Wave Life Sciences on a Huntington’s disease drug, ending their collaboration that first started in 2018 with a $110 million upfront from the Japanese pharma. In an...
View ArticleQ&A: Sanofi’s R&D head reflects on his first year, a post-Dupixent future,...
Almost a year ago, Sanofi made history for the wrong reasons. Last October, CEO Paul Hudson announced strategic changes including boosting R&D spending and pulling the company’s long-term guidance...
View ArticleClik here to view.
Life sciences investor KdT Ventures raises $100M fourth fund
Life sciences VC shop KdT Ventures disclosed its $100 million fourth fund on Wednesday morning, just over two years after announcing an $80 million fund. The seven-year-old firm said the new money will...
View ArticleClik here to view.
Facing a critical week, Pfizer confronts an unsparing foe in Starboard
Starboard Value may have lost its first skirmish with Pfizer. But the activist investor has a track record of protracted, bruising fights for control of companies that’s likely to make it a formidable...
View ArticleClik here to view.
FDA places hold on Novavax's Covid-flu and standalone influenza vaccines
Novavax’s post-Covid path ran into a speed bump Wednesday, as the company announced a clinical hold on its Covid-influenza combination vaccine and its standalone flu shot. The FDA placed the hold after...
View ArticleMedicaid startup Waymark publishes study proving its program slashes ER visits
Investors have been placing bets into startups that help members of low-income households on Medicaid insurance get care. A paper published Wednesday shows that its model is working. San...
View ArticleExscientia’s $15M milestone from Sanofi; Lilly to take Gateway Labs to China
Plus, news about TenNor Therapeutics, Gan & Lee Pharmaceuticals, Orasis and Optus Pharmaceuticals: Exscientia receives $15M milestone from Sanofi: The companies are advancing two programs as part...
View ArticleClik here to view.
FDA leaders kick off rare disease hub to increase cross-center collaboration
FDA officials, including the directors of CBER and CDER, on Wednesday launched a rare disease innovation hub at a public meeting, with an aim to better collaborate and communicate across the two...
View ArticleFirst clinical test of RNA editing restores missing protein in genetic...
An experimental therapy designed to change a single letter of short-lived mRNA molecules has corrected a genetic mutation that prevents people from making a vital protein, Wave Life Sciences announced...
View Article